R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi; Frederik O Meeuwes; Müjde Durmaz; Djamila E Issa; Rolf E Brouwer; Aart Beeker; Anna van Rhenen; Pim G N J Mutsaers; Lara H Böhmer; Marjolein W M van der Poel; Liane Te Boome; Tom van Meerten; Martine E D Chamuleau; Josée M Zijlstra; Mirian Brink; Marcel Nijland

doi:10.1038/s41408-022-00723-4

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi, Frederik O Meeuwes, Müjde Durmaz, Djamila E Issa, Rolf E Brouwer, Aart Beeker, Anna van Rhenen, Pim G N J Mutsaers, Lara H Böhmer, Marjolein W M van der Poel, Liane Te Boome, Tom van Meerten, Martine E D Chamuleau, Josée M Zijlstra, Mirian Brink, Marcel Nijland^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Article number	125
Number of pages	4
Journal	Blood Cancer Journal
Volume	12
Issue number	9
DOIs	https://doi.org/10.1038/s41408-022-00723-4
Publication status	Published - 2 Sept 2022

Access to Document

10.1038/s41408-022-00723-4Licence: CC BY

Cite this

Al-Sarayfi, D., Meeuwes, F. O., Durmaz, M., Issa, D. E., Brouwer, R. E., Beeker, A., van Rhenen, A., Mutsaers, P. G. N. J., Böhmer, L. H., van der Poel, M. W. M., Te Boome, L., van Meerten, T., Chamuleau, M. E. D., Zijlstra, J. M., Brink, M., & Nijland, M. (2022). R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma. Blood Cancer Journal, 12(9), Article 125. https://doi.org/10.1038/s41408-022-00723-4

@article{52b11cbc3cb84de5aa4e0b1f1ed78b38,

title = "R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma",

author = "Diana Al-Sarayfi and Meeuwes, {Frederik O} and M{\"u}jde Durmaz and Issa, {Djamila E} and Brouwer, {Rolf E} and Aart Beeker and {van Rhenen}, Anna and Mutsaers, {Pim G N J} and B{\"o}hmer, {Lara H} and {van der Poel}, {Marjolein W M} and {Te Boome}, Liane and {van Meerten}, Tom and Chamuleau, {Martine E D} and Zijlstra, {Jos{\'e}e M} and Mirian Brink and Marcel Nijland",

year = "2022",

month = sep,

day = "2",

doi = "10.1038/s41408-022-00723-4",

language = "English",

volume = "12",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

Al-Sarayfi, D, Meeuwes, FO, Durmaz, M, Issa, DE, Brouwer, RE, Beeker, A, van Rhenen, A, Mutsaers, PGNJ, Böhmer, LH, van der Poel, MWM, Te Boome, L, van Meerten, T, Chamuleau, MED, Zijlstra, JM, Brink, M & Nijland, M 2022, 'R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma', Blood Cancer Journal, vol. 12, no. 9, 125. https://doi.org/10.1038/s41408-022-00723-4

TY - JOUR

T1 - R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

AU - Al-Sarayfi, Diana

AU - Meeuwes, Frederik O

AU - Durmaz, Müjde

AU - Issa, Djamila E

AU - Brouwer, Rolf E

AU - Beeker, Aart

AU - van Rhenen, Anna

AU - Mutsaers, Pim G N J

AU - Böhmer, Lara H

AU - van der Poel, Marjolein W M

AU - Te Boome, Liane

AU - van Meerten, Tom

AU - Chamuleau, Martine E D

AU - Zijlstra, Josée M

AU - Brink, Mirian

AU - Nijland, Marcel

PY - 2022/9/2

Y1 - 2022/9/2

U2 - 10.1038/s41408-022-00723-4

DO - 10.1038/s41408-022-00723-4

M3 - Comment/Letter to the editor

C2 - 36055987

SN - 2044-5385

VL - 12

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 9

M1 - 125

ER -